Emily Lowe

Kite, a Gilead Company

Dr. Emily Lowe is strategic scientific leader with 15 years of research experience in immunology and host-pathogen interactions. She is currently a Director in Analytical Development within the Process Development Department at Kite Pharma, a Gilead company, where she has been leading the Method Development with focus on potency and cell-based assays since 2015. Prior to joining Kite, Dr. Lowe worked in Dr. Jerome Zack’s laboratory at UCLA where she helped to develop “induction/kill” strategies to eradicate HIV reservoirs in vivo using genetically engineered immunity and the humanized mouse model. During her PhD studies into innate immunity and inflammation, Dr. Lowe split her time between the laboratories of Dr. Genhong Cheng (UCLA) and Dr. Moshe Arditi (Cedars-Sinai) where she discovered that Toll-like Receptor 2 played a protective role in both the epithelial and immune compartments during the development of colitis-associated colorectal cancer. Dr. Lowe’s passion for immunology began at the University of Washington where she completed two B.S. degrees, one in Microbiology and one in Biochemistry.